Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition

Company Remains Confident That Future Launches Will See It Meet Ambitious Targets

Executive Summary

Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track. 

You may also be interested in...



Amgen’s Q1 Overshadowed By Tax Dispute That May Cost $7.1bn To Resolve

First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang. 

Amgen’s Stelara Biosimilar Produces Positive Phase III Results

Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.

Amgen: Humira Interchangeability ‘A Nice To Have, Not A Need To Have’

Amgen management spoke at length about biosimilars during the company’s two-and-a-half-hour-long business review meeting, with the launch of its Amjevita (adalimumab-atto) biosimilar now less than a year away.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel